SCHEMBL28264447

SCHEMBL28264447

NCCCCC(N)C(=O)NC(CO)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 1/20 0.56
▸ DPP8 Q6V1X1 2/20 0.49
▸ DPP9 Q86TI2 2/20 0.49
▸ DPP7 Q9UHL4 2/20 0.49
▸ FOLH1 Q04609 1/20 0.47
▸ GNAI3 P08754 1/20 0.45
▸ GNAO1 P09471 1/20 0.45
▸ GNAI1 P63096 1/20 0.45
▸ TGFBR1 P36897 1/20 0.44
▸ DPP4 P27487 1/20 0.43
▸ MMP2 P08253 2/20 0.43
▸ RNPEP Q9H4A4 1/20 0.42
▸ NMT1 P30419 4/20 0.41
▸ NMT2 O60551 3/20 0.41
▸ CPB2 Q96IY4 1/20 0.40
▸ MMP9 P14780 1/20 0.40
▸ MME P08473 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1923416 1.00 GSR (0.56) GSRDPP8DPP9DPP7FOLH1
SCHEMBL24141455 0.97 GSR (0.53) GSRDPP8DPP9DPP7FOLH1
SCHEMBL29465874 0.97 GSR (0.53) GSRDPP8DPP9DPP7FOLH1
SCHEMBL30943792 0.97 GSR (0.53) GSRDPP8DPP9DPP7FOLH1
SCHEMBL30277638 0.95 GSR (0.51) GSRDPP8DPP9DPP7FOLH1
SCHEMBL30039547 0.95 GSR (0.51) GSRDPP8DPP9DPP7FOLH1
SCHEMBL29943324 0.94 GSR (0.50) GSRDPP8DPP9DPP7FOLH1
SCHEMBL30581338 0.94 GSR (0.50) GSRDPP8DPP9DPP7FOLH1
SCHEMBL29630424 0.94 GSR (0.50) GSRDPP8DPP9DPP7FOLH1
SCHEMBL29592035 0.94 GSR (0.50) GSRDPP8DPP9DPP7FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028601-A1 RECOMBINASE POLYMERASE AMPLIFICATION ABBOTT DIAGNOSTICS SCARBOROUGH INC (US) 2026-01-29 — — US disclosed
US-12227773-B2 Recombinase polymerase amplification ABBOTT DIAGNOSTICS SCARBOROUGH, INC. (US) 2025-02-18 — — US disclosed
US-20230340147-A1 ANTIBODIES SPECIFIC FOR ALPHA-1,6-CORE-FUCOSYLATED PSA AND FUCOSYLATED FRAGMENTS THEREOF ROCHE DIAGNOSTICS OPERATIONS, INC. 2023-10-26 — — US disclosed
US-20230242889-A1 RECOMBINASE POLYMERASE AMPLIFICATION TWISTDX, INC. 2023-08-03 — — US disclosed
EP-4217399-A1 ANTIBODIES SPECIFIC FOR ALPHA-1,6-CORE-FUCOSYLATED PSA AND FUCOSYLATED FRAGMENTS THEREOF Roche Diagnostics GmbH (DE) 2023-08-02 — — EP disclosed
CN-116323670-A Antibodies specific for alpha-1, 6-core-fucosylated PSAs and fucosylated fragments thereof 豪夫迈·罗氏有限公司 2023-06-23 — — CN disclosed
US-11339382-B2 Recombinase polymerase amplification ABBOTT DIAGNOSTICS SCARBOROUGH, INC. (US) 2022-05-24 — — US disclosed
WO-2022063787-A1 ANTIBODIES SPECIFIC FOR ALPHA-1,6-CORE-FUCOSYLATED PSA AND FUCOSYLATED FRAGMENTS THEREOF ROCHE DIAGNOSTICS GMBH (DE) 2022-03-31 — — WO disclosed
CN-109161290-A A kind of preparation method of organic glass anti-pollution layer 中山大学 2019-01-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028601-A1 RECOMBINASE POLYMERASE AMPLIFICATION PCNA, PURB, POLL GSR 3196/4885DPP8 3016/4885DPP9 3029/4885
US-20230340147-A1 ANTIBODIES SPECIFIC FOR ALPHA-1,6-CORE-FUCOSYLATED PSA AND FUCOSYLATED FRAGMENTS THEREOF FUCA1, KLK3, FUCA2 GSR 3783/4885DPP8 1691/4885DPP9 1697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback